Renal Denervation Market Report - 2022 | Key Players include Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc, Mercator MedSystems, Inc., ReCor Medical, Inc. and Renal Dynamics Limited

Renal Denervation Market Report, published by Allied Market Research, forecasts that the global market was valued at $197 million in 2015, and is expected to reach $3,153 million by 2022, supported by a CAGR of 48.5% during the forecast period 2014 - 2022. Symplicity Renal Denervation System is estimated to continue generating highest revenue throughout the forecast period, owing to growing number of product approvals across the globe. Europe held the leading position in the global market in 2015, and is expected to maintain its lead in the future.

Increasing prevalence and incidence of hypertension and blood pressure, changing lifestyle of the people, improvement of healthcare infrastructure in developing countries, and cost effectiveness of the renal denervation procedure as compared to other multidrug treatment therapies propel the market growth. However, stringent approval process for renal denervation devices, and patient discomfort and pain that arises during the procedure hamper the market growth.

Download Now! Sample PDF Brochure @ https://www.alliedmarketresearch.com/request-sample/522

Vessix Renal Denervation System is projected to be the fastest growing segment, with a CAGR of 57.6% from 2016 to 2022, as this system can be used for arteries of variable diameter (has a balloon that can be expanded into variable sizes). In addition, it uses a full-color graphic user interface that increases the accuracy and operation of the device. Boston Scientific, manufacturer of Vessix Renal Denervation System, considers this market to be a potential growth opportunity for expanding its business.

Radiofrequency was the most frequently used technology in the renal denervation market. In addition, it was the major segment in 2015 and is expected to lead throughout the forecast period. Ultrasound is projected to grow at the highest CAGR of 56.4%, as it overcomes the limitations of radiofrequency devices.

Key findings of Renal Denervation Market:
• On the basis of product type, the Symplicity Renal Denervation System segment accounted for the largest share, while Vessix Renal Denervation System is projected to grow at the fastest rate.
• Radiofrequency segment dominated the overall renal denervation market.
• Utrasound is poised to grow at the highest CAGR of 56.4% during the analysis period.
• Europe was the leading geographic market in 2015, and it is projected to lead for the next few years.
• Asia-Pacific is projected to grow at the highest CAGR of 50.6%.

Europes high share is attributed to the early start of this technology in
European countries. In addition, most of the devices in this market have received a CE mark approval and are available for sales in the European region. On the other hand, North America accounts for a small proportion as renal denervation systems have not been approved by the FDA and are available only for investigational purpose in the North American market. Asia-Pacific is expected to grow at the fastest rate during the analysis period, owing to presence of ample growth opportunities in terms of unmet medical needs for the treatment of hypertension, increase in awareness about the use of advanced technologies such as renal denervation systems, and high prevalence rate of resistant hypertension.

Key players have adopted product development as their key strategy to cater to the changing needs of the industry. Major players operating in this market include Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc, Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, St. Jude Medical, Inc., and Terumo Medical Corporation. As of 2015, Medtronic dominated the overall renal denervation market, followed by St. Jude Medical.

TABLE OF CONTENT:

Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.2.2.1 Competitive intelligence of companies and their strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of the suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Competitive rivalry
3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Prevalence of hypertension
3.5.1.2 Changing lifestyle of people
3.5.1.3 Improvement of healthcare infrastructure in developing countries
3.5.1.4 Cost effectiveness of the procedure
3.5.2 Restraints
3.5.2.1 Painful procedure
3.5.2.2 Stringent approval process for renal denervation devices
3.5.3 Opportunities
3.5.3.1 Applications of renal denervation in other diseases
3.5.3.2 Clinical Trials
3.6 Clinical trials
3.6.1 The Symplicity clinical trial program
3.6.1.1 SYMPLICITY HTN-1
3.6.1.2 SYMPLICITY HTN-2
3.6.1.3 SYMPLICITY HTN-3
3.6.1.4 Global SYMPLICITY Registry
3.6.1.5 SYMPLICITY-HF
3.6.1.6 Symplicity Spyral(TM) Catheter Feasibility Study
3.6.1.7 HTN-Japan
3.6.1.8 SYMPLICITY HTN-India
3.6.2 Clinical trials for EnligHTN renal denervation system
3.6.2.1 EnligHTN I Trial
3.6.2.2 EnligHTN II Trial
3.6.2.3 EnligHTN III Trial
3.6.2.4 EnligHTN IV Trial
3.6.2.5 EnligHTNment Trial
3.6.3 Other clinical trials

Chapter: 4 WORLD RENAL DENERVATION MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Symplicity
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Vessix (V2)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 EnligHTN
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.5 Paradise
4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast
4.6 Iberis
4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast
4.7 Others
4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast

Chapter: 5 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Radiofrequency
5.2.1 Market size and forecast
5.3 Ultrasound
5.3.1 Market size and forecast
5.4 Micro-infusion
5.4.1 Market size and forecast

Chapter: 6 WORLD RENAL DENERVATION MARKET, BY GEOGRAPHY, 2014-2022
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S. market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico market size and forecast
6.3 Europe
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Germany market size and forecast
6.3.5 France market size and forecast
6.3.6 U.K. market size and forecast
6.3.7 Italy market size and forecast
6.3.8 Spain market size and forecast
6.3.9 Rest of Europe market size and forecast
6.4 Asia-Pacific
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan market size and forecast
6.4.5 China market size and forecast
6.4.6 India market size and forecast
6.4.7 Australia market size and forecast
6.4.8 New Zealand market size and forecast
6.4.9 Others market size and forecast
6.5 LAMEA
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Brazil market size and forecast
6.5.5 South Africa market size and forecast
6.5.6 Saudi Arabia market size and forecast
6.5.7 Rest of LAMEA market size and forecast

Chapter: 7 COMPANY PROFILES
7.1 Ablative Solutions, Inc.
7.1.1 Company Overview
7.1.2 Company Snapshot
7.1.3 Operating Business Segments
7.1.4 Key Strategic Moves & Developments
7.2 Boston Scientific Corporation
7.2.1 Company Overview
7.2.2 Operating Business Segments
7.2.3 Business Performance
7.2.4 Key Strategic Moves & Developments
7.3 Cardiosonic Ltd
7.3.1 Company Overview
7.3.2 Company Snapshot
7.3.3 Key Strategic Moves & Developments
7.4 Kona Medical, Inc.
7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Key Strategic Moves & Developments
7.5 Medtronic plc
7.5.1 Company Overview
7.5.2 Company Snapshot
7.5.3 Operating Business Segments
7.5.4 Business Performance
7.5.5 Key Strategic Moves & Developments
7.6 Mercator MedSystems, Inc.
7.6.1 Company Overview
7.6.2 Company Snapshot
7.6.3 Operating Business Segments
7.6.4 Key Strategic Moves & Developments
7.7 ReCor Medical, Inc.
7.7.1 Company Overview
7.7.2 Company Snapshot
7.7.3 Key Strategic Moves & Developments
7.8 Renal Dynamics Limited
7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Key Strategic Moves & Developments
7.9 St. Jude Medical, Inc.
7.9.1 Company Overview
7.9.2 Operating Business Segments
7.9.3 Business Performance
7.9.4 Key Strategic Moves & Developments
7.10 Terumo Corporation
7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating Business Segments
7.10.4 Business Performance
7.10.5 Key Strategic Moves & Developments

Check offers and discount on this report @ https://www.alliedmarketresearch.com/get-discount/522

About Us:
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.